Alliancebernstein L.P. Cuts Stock Position in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Alliancebernstein L.P. reduced its stake in Dianthus Therapeutics, Inc. by 11.6% during the first quarter, now holding approximately 3.19% of the company valued at $18.6 million after selling 134,154 shares.
• Wall Street analysts have increased price targets for Dianthus Therapeutics, with Guggenheim raising its target from $92.00 to $100.00 and multiple firms maintaining a consensus rating of "Buy".
• Dianthus Therapeutics reported a quarterly EPS of ($0.88), missing analysts' expectations, alongside a significant negative net margin of 2,364.56% and revenue of $0.19 million against a forecast of $0.87 million.

Alliancebernstein L.P. lessened its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 11.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,025,622 shares of the company's stock after selling 134,154 shares during the quarter. Alliancebernstein L.P. owned approximately 3.19% of Dianthus Therapeutics worth $18,605,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of DNTH. US Bancorp DE raised its holdings in shares of Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after buying an additional 1,510 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at $59,000. GAMMA Investing LLC raised its holdings in shares of Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after buying an additional 3,758 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Dianthus Therapeutics by 21.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,468 shares of the company's stock valued at $207,000 after buying an additional 1,647 shares during the period. Finally, Invesco Ltd. increased its holdings in Dianthus Therapeutics by 38.7% during the 1st quarter. Invesco Ltd. now owns 15,978 shares of the company's stock worth $290,000 after purchasing an additional 4,457 shares during the period. Hedge funds and other institutional investors own 47.53% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on DNTH shares. Guggenheim upped their price target on Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday. Raymond James Financial restated an "outperform" rating and set a $63.00 price target (up previously from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday. HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday. Robert W. Baird upped their price target on Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an "outperform" rating in a report on Tuesday. Finally, William Blair started coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They set an "outperform" rating on the stock. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $60.67.

Dianthus Therapeutics Stock Performance

DNTH opened at $37.90 on Thursday. Dianthus Therapeutics, Inc. has a one year low of $13.36 and a one year high of $38.25. The company has a market cap of $1.22 billion, a P/E ratio of -11.66 and a beta of 1.46. The business's 50-day simple moving average is $22.28 and its 200-day simple moving average is $20.32.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The business had revenue of $0.19 million during the quarter, compared to analysts' expectations of $0.87 million. As a group, analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.